Selection of the optimal dose for an ultra-short course subcutaneous immunotherapy (SCIT) for Rhinoconjunctivitis for Birch Allergic patients

被引：0

作者：

Worm, Margitta ^{[1
]}

Zielen, Stefan ^{[2
]}

Higenbottam, Tim ^{[3
]}

Pfaar, Oliver ^{[4
]}

Mosges, Ralph ^{[5
]}

Aberer, Werner ^{[6
]}

Kramer, Matthias ^{[7
]}

Skinner, Murray ^{[3
]}

Lees, Bev ^{[3
]}

机构：

[1] Charite Univ Med Berlin, Berlin, Germany

[2] Goethe Univ Frankfurt Main, Klinikum Frankfurt 2Univ, Frankfurt, Germany

[3] Allergy Therapeut, Worthing, England

[4] Univ Med Mannheim, Dept Otorhinolaryngol Head & Neck Surg, Mannheim, Germany

[5] Univ Cologne, Cologne, Germany

[6] Med Univ Graz, Dept Dermatol & Venerol, Graz, Austria

[7] Bencard GmbH, Munich, Germany

来源：

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2017年 / 139卷 / 02期

关键词：

D O I：

10.1016/j.jaci.2016.12.491

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

478

引用

页码：AB150 / AB150

页数：1

共 50 条

[21] Selection of patients for sublingual immunotherapy (SLIT) versus subcutaneous immunotherapy (SCIT) (vol 36, pg 100, 2015)
Tabatabaian, F.
Casale, T. B.
ALLERGY AND ASTHMA PROCEEDINGS, 2015, 36 (03) : 217 - 217
[22] Sublingual allergen immunotherapy with a liquid birch pollen product in patients with seasonal allergic rhinoconjunctivitis with or without asthma
Pfaar, Oliver
Bachert, Claus
Kuna, Piotr
Panzner, Petr
Dzupinova, Maria
Klimek, Ludger
van Nimwegen, Maroesja J.
Boot, Johan D.
Yu, Donghui
Opstelten, Dirk Jan E.
de Kam, Pieter-Jan
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 143 (03) : 970 - 977
[23] Tolerability of ultra-short updosing phases in a compact sublingual immunotherapy dose regimen
Piller, M.
Preussner, L.
Drachenberg, K.
ALLERGY, 2011, 66 : 624 - 624
[24] Design of a phase III short-term efficacy study with allergen specific immunotherapy in patients with birch pollen induced allergic rhinitis/rhinoconjunctivitis
van Nimwegen, M.
Pfaar, O.
Kuna, P.
Panzner, P.
Dzupinova, M.
Boot, D.
Bachert, C.
ALLERGY, 2015, 70 : 454 - 454
[25] Quality of life improvement in patients suffering from tree pollen-related rhinoconjunctivitis and asthma: 1 year follow-up of a 3 year ultra-short course subcutaneous immunotherapy containing monophosphoryl-lipid A
Rabe, U.
Fiedler, G.
Piller, M.
ALLERGY, 2011, 66 : 630 - 631
[26] Quality of life improvement in patients suffering from grass pollen-related rhinoconjunctivitis and asthma: 1 year follow-up of a 3 year ultra-short course subcutaneous immunotherapy containing monophosphoryl-lipid A
Rabe, U.
Fiedler, G.
Piller, M.
ALLERGY, 2011, 66 : 630 - 630
[27] Sublingual immunotherapy with a liquid birch pollen extract is similarly effective for younger and older patients with birch pollen induced allergic rhinitis/rhinoconjunctivitis
Pfaar, O.
Bachert, C.
Kuna, P.
Panzner, P.
Dzupinova, M.
Yu, D.
Mantikou, E.
Moed, H.
Klimek, L.
De Kam, P. J.
ALLERGY, 2017, 72 : 275 - 276
[28] Ultra-short-course booster is effective in recurrent grass pollen-induced allergic rhinoconjunctivitis
Pfaar, O.
Lang, S.
Pieper-Fuerst, U.
Astvatsatourov, A.
Gerich, F.
Klimek, L.
Kramer, M. F.
Reydelet, Y.
Shah-Hosseini, K.
Moesges, R.
ALLERGY, 2018, 73 (01) : 187 - 195
[29] Phase I study of subcutaneous allergen immunotherapy with Dermatophagoides pteronyssinus in patients with allergic rhinoconjunctivitis with or without asthma
Fernandez de Rojas, Dolores Hernandez
Antepara Ercoreca, Ignacio
Ponte Tellechea, Ana
Ibanez Echevarria, Ethel
Jauregui Presa, Ignacio
Gamboa Setien, Pedro
Asturias, Juan A.
Landeta Manzano, Araitz
Madariaga Goirigolzarri, Begona
IMMUNOTHERAPY, 2015, 7 (02) : 89 - 99
[30] Patient-relevant benefit of sublingual immunotherapy (SLIT) with a 300 IR birch pollen extract in patients with allergic rhinoconjunctivitis
Hadler, M.
Karagiannis, E.
Feuerhahn, J.
Blome, C.
Augustin, M.
ALLERGY, 2016, 71 : 247 - 247

← 1 2 3 4 5 →